These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20200357)

  • 1. Palmitoylation of oncogenic NRAS is essential for leukemogenesis.
    Cuiffo B; Ren R
    Blood; 2010 Apr; 115(17):3598-605. PubMed ID: 20200357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A.
    Zhao H; Liu P; Zhang R; Wu M; Li D; Zhao X; Zhang C; Jiao B; Chen B; Chen Z; Ren R
    J Hematol Oncol; 2015 Dec; 8():132. PubMed ID: 26715448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.
    Parikh C; Subrahmanyam R; Ren R
    Blood; 2006 Oct; 108(7):2349-57. PubMed ID: 16763213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation.
    Wu M; Huang J; Zhang J; Benes C; Jiao B; Ren R
    Mol Cancer Ther; 2017 Jan; 16(1):57-67. PubMed ID: 27760835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
    Tyner JW; Erickson H; Deininger MW; Willis SG; Eide CA; Levine RL; Heinrich MC; Gattermann N; Gilliland DG; Druker BJ; Loriaux MM
    Blood; 2009 Feb; 113(8):1749-55. PubMed ID: 19075190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia.
    Ren JG; Xing B; Lv K; O'Keefe RA; Wu M; Wang R; Bauer KM; Ghazaryan A; Burslem GM; Zhang J; O'Connell RM; Pillai V; Hexner EO; Philips MR; Tong W
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37317963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice.
    Zambetti NA; Firestone AJ; Remsberg JR; Huang BJ; Wong JC; Long AM; Predovic M; Suciu RM; Inguva A; Kogan SC; Haigis KM; Cravatt BF; Shannon K
    Blood; 2020 May; 135(20):1772-1782. PubMed ID: 32219446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique dependence on Sos1 in
    You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
    Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse model for NRAS-induced leukemogenesis.
    Parikh C; Ren R
    Methods Enzymol; 2008; 439():15-24. PubMed ID: 18374153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
    Kim WI; Matise I; Diers MD; Largaespada DA
    Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.
    Xu J; Hedberg C; Dekker FJ; Li Q; Haigis KM; Hwang E; Waldmann H; Shannon K
    Blood; 2012 Jan; 119(4):1032-5. PubMed ID: 22144181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
    Zhao S; Zhang Y; Sha K; Tang Q; Yang X; Yu C; Liu Z; Sun W; Cai L; Xu C; Cui S
    Cell Physiol Biochem; 2014; 33(1):78-87. PubMed ID: 24480914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
    Huang X; Schwind S; Santhanam R; Eisfeld AK; Chiang CL; Lankenau M; Yu B; Hoellerbauer P; Jin Y; Tarighat SS; Khalife J; Walker A; Perrotti D; Bloomfield CD; Wang H; Lee RJ; Lee LJ; Marcucci G
    Oncotarget; 2016 Sep; 7(37):59273-59286. PubMed ID: 27517749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms for regulation of RAS palmitoylation and plasma membrane trafficking in hematopoietic malignancies.
    Yu F; Qian Z
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37317974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras.
    Kalra R; Paderanga DC; Olson K; Shannon KM
    Blood; 1994 Nov; 84(10):3435-9. PubMed ID: 7949098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
    Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
    Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
    Wang J; Liu Y; Li Z; Wang Z; Tan LX; Ryu MJ; Meline B; Du J; Young KH; Ranheim E; Chang Q; Zhang J
    Blood; 2011 Jul; 118(2):368-79. PubMed ID: 21586752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ras palmitoylation is necessary for N-Ras activation and signal propagation in growth factor signalling.
    Song SP; Hennig A; Schubert K; Markwart R; Schmidt P; Prior IA; Böhmer FD; Rubio I
    Biochem J; 2013 Sep; 454(2):323-32. PubMed ID: 23758196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.
    Wolf S; Rudolph C; Morgan M; Büsche G; Salguero G; Stripecke R; Schlegelberger B; Baum C; Modlich U
    Oncogene; 2013 Jun; 32(25):3028-38. PubMed ID: 22847614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.